drugset / Trial / NCT02040883

Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia

NCT02040883

Phase 4 Unknown 100 enrolled Qingyun Yin
RandomizedParallel-groupSingle-blindTreatment

Summary

Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia

Timeline

Start
2014-02
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tandospirone Small molecule 30 mg
Background Aripiprazole Other / unclassified
Background Olanzapine Small molecule
Background Quetiapine Small molecule
Background Risperidone Other / unclassified
Background Ziprasidone Small molecule

Indications